Benjamin J. Zeskind - 23 Jun 2026 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: PRESIDENT AND CEO, Director
Issuer ticker: IMRX
Reported as of: 23 Jun 2026
Net transaction value: +$10,948
SEC form: 4
Accepted by SEC: 24 Jun 2026, 16:11:29 UTC
Prior SEC filing: 05 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind

Key filing fact

Benjamin J. Zeskind filed Form 4 for Immuneering Corp (IMRX) on 24 Jun 2026.

Key facts

This page summarizes Benjamin J. Zeskind's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 24 Jun 2026, 16:11.

Change

Previous filing in this sequence was filed on 05 Feb 2026.
Current net transaction value: +$10,948.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001870062 Primary reporting owner

Zeskind Benjamin J.

Relationship: PRESIDENT AND CEO, Director
Address: 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Signature: /s/ Michael D. Bookman, Attorney-in-Fact for Benjamin J. Zeskind
Signature date: 24 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IMRX transaction

Class A Common Stock

Purchase

Transaction value: $10,948
Shares: +2,400
Change %: +0.1%
Price: $4.56
Shares after: 2,315,252
Date: 23 Jun 2026
Ownership: Direct
Footnotes: F1

IMRX holding

Class A Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 894,927
Date: 23 Jun 2026
Ownership: See Foonote
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

This transaction was executed in multiple trades through a broker-dealer at prices ranging from $4.55 to $4.59. The price reported in this column reflects the weighted average purchase price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares acquired at each price.

Footnote F2

Held by the Benjamin J. Zeskind 2020 Family Trust, where Lisa Schwartz, Dr. Zeskind's spouse, serves as sole trustee.